Published • loading... • Updated
Switzerland’s Sandoz Pivots to Biosimilars, Expects Rapid Mid-Term Growth
The drugmaker said biosimilars will drive most sales as it seeks 100 products by 2040 and mid-to-high single-digit annual growth through 2030.
- On Tuesday, Swiss drug maker Sandoz announced a strategic pivot from generics to biosimilars at its capital markets day, aiming to more than double net sales by 2035 while pursuing what it calls a "golden decade."
- Chief Executive Richard Saynor noted that $650 billion worth of branded products face patent expiration over the next decade, creating a prime market opportunity for biosimilars expansion.
- To support its Bio100 ambition of reaching 100 drugs by 2040, Sandoz committed more than $1.1 billion to a Ljubljana development center and announced $300 million for a new manufacturing facility.
- The company targets mid-to-high single-digit annual net sales growth from 2025 to 2030 and reaffirmed its prior 2028 outlook; shares rose around 19% year-to-date following the strategy update.
- While RBC analysts described the mid-term targets as "light," they noted the 2035 goals are "more ambitious and show an expected acceleration through the early 2030s," a rich period for new biosimilar launches.
Insights by Ground AI
17 Articles
17 Articles
The global leader in generic and biosimilar medicines hopes to double its sales by 2035.
·Paris, France
Read Full Article
Basel-based generics manufacturer Sandoz sets ambitious growth targets. However, the problem with Trump's customs threats is unresolved. The company still lacks a production facility in the US.
·Zürich, Switzerland
Read Full Article
Swiss pharmaceutical giant Sandoz is planning to build a new production facility in Ljubljana for active ingredients for biosimilar medicines worth €258 million. It will enable clinical and commercial production, and is due to be established in 2029.
·Ljubljana, Slovenia
Read Full Article
Production is expected to begin in 2029, and the new center will support both clinical and commercial production.
·Ljubljana, Slovenia
Read Full Article
Switzerland's Sandoz pivots to biosimilars, expects rapid ...
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left2Leaning Right5Center3Last UpdatedBias Distribution50% Right
Bias Distribution
- 50% of the sources lean Right
50% Right
L 20%
C 30%
R 50%
Factuality
To view factuality data please Upgrade to Premium
